A case of Sézary syndrome in a patient during treatment with baricitinib for seronegative rheumatoid arthritis

The risk of developing malignancies including cutaneous T-cell lymphoma with use of Janus kinase inhibitors is of concern. Here, we describe a case of Sézary syndrome in a patient during treatment with baricitinib for seronegative rheumatoid arthritis.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical and experimental dermatology 2023-03, Vol.48 (4), p.391-393
Hauptverfasser:	Saito, Kandai, Shimauchi, Takatoshi, Kageyama, Reiko, Furukawa, Seri, Suzuki, Norihito, Ginoza, Atsuyoshi, Moriki, Mutsumi, Ito, Taisuke, Honda, Tetsuya
Format:	Artikel
Sprache:	eng
Schlagworte:	Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Azetidines - adverse effects Humans Sezary Syndrome - drug therapy Skin Neoplasms - drug therapy Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The risk of developing malignancies including cutaneous T-cell lymphoma with use of Janus kinase inhibitors is of concern. Here, we describe a case of Sézary syndrome in a patient during treatment with baricitinib for seronegative rheumatoid arthritis.
ISSN:	0307-6938 1365-2230
DOI:	10.1093/ced/llac124